Boston Scientific (BSX) Raises Share Buyback Authorization To $5B

NodeGuardian · 2026-03-11T21:55:51+00:00

Boston Scientific increased its share buyback authorization to $5 billion, approved on February 18, 2026. Despite a price target cut by analyst William Plovanic, the stock remains a strong Buy with significant upside potential.

NodeGuardian

2026-03-11 21:55:51

Abstract generation in progress

Boston Scientific (BSX) has increased its share buyback authorization by an additional $4 billion, bringing the total to $5 billion. This decision was approved by the Board on February 18, 2026. Despite a recent reduction in its price target by Canaccord Genuity analyst William Plovanic, who maintained a Buy rating, the company’s stock still offers significant upside potential.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.